Zurich-Schlieren, November 7, 2016.
Dear Friends, Colleagues, Partners and Shareholders,
I would like to inform you that I have resigned from my position as the Chief Executive Officer of Molecular Partners due to health reasons. The time has come for me to focus my energy on myself and my family. I remain a member of the Board of Directors.
Our Board of Directors has appointed Patrick Amstutz, Ph.D., the Chief Operating Officer of Molecular Partners, as the acting Chief Executive Officer as we evaluate the most suitable successor from within or outside the company.
Patrick is fully integrated in all facets of the company’s operations and, along with our board chairman, successfully led the company during my medical leave of absence in 2015. Patrick’s proven leadership track record, combined with his deep understanding of our company, our technology and our products, puts him in a very strong position to successfully lead Molecular Partners going forward.
As a co-founder of Molecular Partners, it has been my privilege to help the company grow from a small, private start-up into a clinical-stage public company. In recent years, the company completed a successful initial public offering; initiated Phase III development of abicipar, our lead asset in ophthalmology (in collaboration with Allergan); and generated the first compelling clinical data supporting systemic use of a multi-DARPin therapy in oncology.
The remarkable progress of Molecular Partners is only possible with the hard work and support of our talented colleagues, dedicated partners, shareholders and friends. From the first days of the company, we have worked together with a deep appreciation for each other, always for the greater good. Working in partnership to advance medicine and improve health has become a core value of Molecular Partners.
Thank you for the opportunity to work alongside each of you over these many years. Molecular Partners is well positioned for continued success. I look forward to watching the company continue to grow and contributing to its success in my continued role on the Board of Directors.